Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis.

ESMO Open · 2022 · PMC9271478 · PMID 35427835

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

First-line durvalumab, nivolumab and ipilimumab did not reach statistical significance either for OS or for PFS; tislelizumab and camrelizumab did not demonstrate benefit in OS, but analysis is based on very immature data.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.